122MO Nivolumab (NIVO) + ipilimumab (IPI) as first-line (1L) treatment (tx) for patients (pts) with advanced NSCLC (aNSCLC) and baseline (BL) brain metastases (mets): Intracranial and systemic outcomes from CheckMate 227 Part 1

Martin Reck, Tudor–Eliade Ciuleanu, Adam Płużański, J.S. Lee, R. Bernabe Caro, Helena Linardou, J. Burgers, Carlos Gallardo, Makoto Nishio, Solange Peters, Luis Paz‐Ares, Matthew D. Hellmann, Hossein Borghaei, Suresh S. Ramalingam, Kenneth J. O’Byrne, Nan Hu, Judith Bushong, Laura J. Eccles, Diederik J. Grootendorst, Julie R. Brahmer